Fortis Group Advisors, LLC Lexicon Pharmaceuticals, Inc. Transaction History
Fortis Group Advisors, LLC
- $551 Billion
- Q2 2025
A detailed history of Fortis Group Advisors, LLC transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Fortis Group Advisors, LLC holds 57,800 shares of LXRX stock, worth $64,736. This represents 0.01% of its overall portfolio holdings.
Number of Shares
57,800
Previous 37,800
52.91%
Holding current value
$64,736
Previous $17.4 Million
255.07%
% of portfolio
0.01%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding LXRX
# of Institutions
134Shares Held
198MCall Options Held
310KPut Options Held
77.3K-
Artal Group S.A. Luxembourg, N4136MShares$153 Million100.0% of portfolio
-
Black Rock Inc. New York, NY9.89MShares$11.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.56MShares$10.7 Million0.0% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY8.21MShares$9.2 Million0.03% of portfolio
-
Siren, L.L.C. New York, NY3.52MShares$3.94 Million0.09% of portfolio
About LEXICON PHARMACEUTICALS, INC.
- Ticker LXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 188,726,000
- Market Cap $211M
- Description
- Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...